Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in…


– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –

Read more:
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in...

Related Posts